Psyence Biomedical Ltd. (PBM)
Develops psilocybin-based medicines to treat cancer patients' emotional distress
$3.16+0.04%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-96.6%
The outlook
PBM is trading near its 52-week low with minimal analyst coverage. The stock sits below both its 50- and 200-day moving averages, reflecting a weak near-term trend. Market sentiment appears notably bearish based on available data.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Market cap
—
52-wk high
$371.09
52-wk low
$1.92
50-day avg
$3.39
200-day avg
$29.77
Trailing P/E
—